Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 24,100 shares at $91.96 ($2.2M) on 2024-12-19, disclosed to the SEC on 2024-12-20.
Scheduled sale ($2.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $88.28 | 3,920 | $346K | 16.1% |
| 2 | $88.28 | 3,920 | $346K | 16.1% |
| 3 | $89.01 | 5,180 | $461K | 21.4% |
| 4 | $89.01 | 5,180 | $461K | 21.4% |
| 5 | $91.15 | 3,800 | $346K | 16.1% |
| 6 | $91.96 | 2,100 |
| $193K |
| 9.0% |
| Total | $89.37 avg | 24,100 | $2.2M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |